Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787306 | 0.85 | CNR1 (0.47) | CNR1ROCK2MEN1KMT2ANPC1 | |
| SCHEMBL3339991 | 0.83 | MEN1 (0.44) | MEN1KMT2ANPC1TP53RAB9A | |
| Trifluoroacetic Acid SCHEMBL3341662 | 0.83 | OPRM1 (0.43) | ROCK2MEN1KMT2AKDM4EHTR5A | |
| SCHEMBL16203744 | 0.83 | NR4A2 (0.44) | CNR1MEN1KMT2AKDM4EMPO | |
| SCHEMBL12607764 | 0.82 | OPRM1 (0.47) | CNR1ROCK2MEN1KMT2AKDM4E | |
| SCHEMBL1790026 | 0.78 | OPRM1 (0.44) | ROCK2MEN1KMT2AKDM4EMPO | |
| SCHEMBL12651459 | 0.72 | KDM4E (0.51) | KDM4EMPO | |
| SCHEMBL3342513 | 0.69 | MEN1 (0.44) | MEN1KMT2ANPC1TP53RAB9A | |
| Trifluoroacetic Acid SCHEMBL1787305 | 0.68 | OPRM1 (0.44) | MEN1KMT2AKDM4E | |
| SCHEMBL4921613 | 0.66 | CNR1 (0.73) | CNR1MEN1KMT2ANAMPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | CNR1 43/4885ROCK2 3629/4885MEN1 4375/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | CNR1 22/4885ROCK2 2925/4885MEN1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.